Molecular Determinants of Response to PD-L1 Blockade across Tumor Types

Researchers complemented PD-L1 immunohistochemistry and tumor mutation burden with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that could predict response to checkpoint blockade across tumor types.